Syndax Pharmaceuticals Inc
Research Syndax Pharmaceuticals Inc (SNDX) on Bullrun: market cap USD 1.78B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSNDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.78B
- Financial periodQ2 2026
- RevenueUSD 72.79M
- Net income-USD 49.36M
- Free cash flow-USD 30.31M
- Gross margin95.6%
Valuation Snapshot
latest market cap is USD 1.78B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 172.35M | -USD 285.40M | -USD 323.17M | 96.1% | -3.29 | USD 134.93M | USD 343.91M | USD 64.63M |
| FY2024 | USD 23.68M | -USD 318.80M | -USD 274.90M | n/a | -3.72 | USD 154.08M | USD 343.68M | USD 288.12M |
| FY2023 | USD 0 | -USD 209.40M | -USD 160.60M | n/a | -2.98 | USD 295.39M | USD 0 | USD 554.20M |
| FY2022 | USD 0 | -USD 149.30M | -USD 133.68M | n/a | -2.46 | USD 74.36M | USD 21.09M | USD 467.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.78B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.84B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.13B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.83B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.73B | 2545.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.20B | 47.6 | n/a | n/a |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Syndax Pharmaceuticals Inc's market cap?
Syndax Pharmaceuticals Inc's market capitalization is USD 1.78B.
What does Syndax Pharmaceuticals Inc do?
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.